$0.47 $0.00 (0.2%)

04:00 PM EDT on 09/20/19

Synthetic Biologics, Inc. (NYSEMKT:SYN)

CAPS Rating: 2 out of 5

A development-stage, specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases.

Current Price $0.47 Mkt Cap $8.67
Open $0.47 P/E Ratio 0.00
Prev. Close $0.47 Div. (Yield) $0.00 (0.0%)
Daily Range $0.47 - $0.48 Volume 23,595
52-Wk Range $0.38 - $0.85 Avg. Daily Vol. 7

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

46 Outperform
16 Underperform
 

All-Star Players

3 Outperform
8 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NYSEMKT:SYN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

vpdjuric (< 20)
Submitted January 21, 2011

I have to respectfully disagree with zz below. Zinth is definitely not a cure for Alzheimer's, and it is not advertised as such. It is a prescription medical food meant to slow cognitive degradation seen in Alzheimer's and similar diseases. The… More

zzlangerhans (99.83)
Submitted November 30, 2015

Synthetic Biologics seems to be back in fashion among the momentum crowd, but the company will always be a name-changing, shape-shifting, perma-disappointer to me. Traders are looking ahead to topline data from the phase II trial of SYN-010 in IBS-C,… More

NYSEMKT:SYN VS S&P 500 (SPY)

Fools bullish on NYSEMKT:SYN are also bullish on:

Fools bearish on NYSEMKT:SYN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about SYN.

Recs

0
Member Avatar allstar31 (99.89) Submitted: 1/24/2015 11:20:58 PM : Underperform Start Price: $53.20 NYSE MKT:SYN Score: +144.86

This is a reup of a former Red thumb.
-----
Crap pharma. Has not been profitable in 10 years.

Recs

0
Member Avatar QUINT27 (< 20) Submitted: 2/21/2014 7:15:16 AM : Outperform Start Price: $95.55 NYSE MKT:SYN Score: -161.22

Trimesta results in April will double stock value.

Recs

2
Member Avatar vpdjuric (< 20) Submitted: 1/21/2011 3:02:18 AM : Outperform Start Price: $50.75 NYSE MKT:SYN Score: -230.57

I have to respectfully disagree with zz below. Zinth is definitely not a cure for Alzheimer's, and it is not advertised as such. It is a prescription medical food meant to slow cognitive degradation seen in Alzheimer's and similar diseases. The hypothesis is that since there is a significant correlation between zinc deficiency and degradation of cognitive function, taking zinc supplements may slow cognitive deterioration. Zinth is comprised of zinc and cysteine, and both components are generally regarded as safe, which reduces the number of hurdles Adeona has to overcome to get it to market. Zinth's differentiation from standard zinc supplements is its ease of digestion, whereas common zinc supplements commonly have side effects of indigestion, nausea, and heartburn. Anecdotal results have been positive so far:

http://www.crainsdetroit.com/article/20110102/SUB01/301029993/alzheimers-trial-may-win-deal-for-adeona-supplement-interests-drug-firms#

Beyond Zinth, they are also in various stages of testing 4 other drugs for drugs for multiple sclerosis, fibromyalgia, age-related macular degeneration and rheumatoid arthritis, a couple of which have blockbuster potential. The management team, led by Dr. Kuo, is stellar, and insiders own 47% of the company. Recently, they added Dr. Anand Prasad to the team, a pioneer in zinc research.

Adeona has already received term sheets for Zinth from potential pharma partners, but nothing has been announced yet. The final data from the Zinc trials will be announced in March, although a partnership may come before then. Kuo has announced that Adeona will hold an investor day on February 8th, during which he will discuss plans for Zinth. If a partnership deal has been signed, that would probably be the day he announced it...

Leaderboard

Find the members with the highest scoring picks in SYN.

Score Leader

glenn12345

glenn12345 (99.98) Score: +330.13

The Score Leader is the player with the highest score across all their picks in SYN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Seal07 < 20 8/15/2011 Underperform 1Y $28.02 -98.34% +149.81% +248.15 0 Comment
Bill292 29.63 1/3/2012 Underperform 5Y $43.75 -98.94% +132.77% +231.70 0 Comment
mainakn 75.33 3/22/2011 Underperform 3M $60.90 -99.24% +130.27% +229.51 0 Comment
EvilEmpire 29.89 1/12/2012 Underperform 5Y $59.50 -99.22% +130.25% +229.47 0 Comment
SpecEdSquadron 97.86 4/17/2012 Underperform NS $60.20 -99.23% +116.44% +215.67 0 Comment
pear4000 31.10 8/15/2012 Underperform 3M $71.37 -99.35% +111.48% +210.83 0 Comment
cfayles < 20 10/25/2007 Underperform 5Y $236.25 -99.80% +107.30% +207.10 0 Comment
SissorsC 30.64 10/5/2007 Underperform 3Y $236.25 -99.80% +101.63% +201.43 0 Comment
FesterFumble 50.54 4/28/2014 Underperform 5Y $101.15 -99.54% +59.50% +159.04 0 Comment
TimeToBuy 85.52 1/7/2015 Underperform 5Y $56.00 -99.17% +48.12% +147.29 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackMaximGroup 64.08 9/30/2013 Outperform NS $68.95 -99.32% +78.13% -177.46 0 Comment